Research progress in medicinal treatment of autism spectrum disorders
10.16438/j.0513-4870.2017-0912
- VernacularTitle:孤独症谱系障碍的药物治疗研究进展
- Author:
Xiang-qing XU
1
;
Ke-wei WANG
2
Author Information
1. Jiangsu Nhwa Pharmaceutical Co., Ltd., Xuzhou 221116, China
2. School of Pharmacy, Qingdao University, Qingdao 266021, China
- Publication Type:REVIEWS
- Keywords:
autism spectrum disorders;
drug therapy;
antipsychotic;
antidepressant;
aripiprazole;
risperidone
- From:
Acta Pharmaceutica Sinica
2018;53(3):321-327
- CountryChina
- Language:Chinese
-
Abstract:
Autism spectrum disorders (ASD) are a group of behaviorally defined, etiologically heterogeneous neurodevelopmental disorders characterized by impairment in social reciprocity, disturbances in language and various types of repetitive behaviors. The etiology and pathogenic mechanism of ASD are still unclear and there is no effective treatment available yet. ASD treatment includes behavioral and medicinal interventions. Behavioral interventions are the first line of treatment for ASD, alleviating core symptoms. Medicinal treatments, exert limited effect towards the core symptoms, represent an aide to the behavioral intervention and mainly apply to the so-called associated behavioral symptoms, such as irritability, aggression, self-injury, anxiety, insomnia, hyperactivity, low attention and compulsive behavior. A wide range of different agents are currently being tested in the preclinical and clinical studies, which include antipsychotics, antidepressants, anticonvulsants, anxiolytics, anti-infective drugs, glutamate receptor modulators, GABA receptor modulators, mTOR inhibitors and neuropeptides, etc. The purpose of present review is to cover the research advances in drug development and medicinal treatment of autism spectrum disorders.
